CN112646837A - Recombinant human adiponectin expression vector, vector construction method and expression method - Google Patents
Recombinant human adiponectin expression vector, vector construction method and expression method Download PDFInfo
- Publication number
- CN112646837A CN112646837A CN201910966965.9A CN201910966965A CN112646837A CN 112646837 A CN112646837 A CN 112646837A CN 201910966965 A CN201910966965 A CN 201910966965A CN 112646837 A CN112646837 A CN 112646837A
- Authority
- CN
- China
- Prior art keywords
- human adiponectin
- recombinant human
- expression vector
- plasmid
- restriction enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 title claims abstract description 67
- 102000057799 human ADIPOQ Human genes 0.000 title claims abstract description 65
- 239000013604 expression vector Substances 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 25
- 238000010276 construction Methods 0.000 title claims abstract description 11
- 239000013598 vector Substances 0.000 title abstract description 5
- 239000012634 fragment Substances 0.000 claims abstract description 32
- 239000013612 plasmid Substances 0.000 claims abstract description 31
- 239000002299 complementary DNA Substances 0.000 claims abstract description 20
- 241000699800 Cricetinae Species 0.000 claims abstract description 19
- 210000001672 ovary Anatomy 0.000 claims abstract description 19
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 16
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 16
- 108020004705 Codon Proteins 0.000 claims abstract description 5
- 239000002773 nucleotide Substances 0.000 claims abstract description 5
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 5
- 238000005457 optimization Methods 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 33
- 108091008146 restriction endonucleases Proteins 0.000 claims description 28
- 108020002326 glutamine synthetase Proteins 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 11
- 150000001413 amino acids Chemical group 0.000 claims description 10
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 9
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 9
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 8
- 239000006285 cell suspension Substances 0.000 claims description 8
- 108091033409 CRISPR Proteins 0.000 claims description 7
- 238000010354 CRISPR gene editing Methods 0.000 claims description 7
- 238000004520 electroporation Methods 0.000 claims description 7
- 238000001976 enzyme digestion Methods 0.000 claims description 6
- 238000012163 sequencing technique Methods 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000002457 bidirectional effect Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 238000001890 transfection Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 102000011690 Adiponectin Human genes 0.000 description 29
- 108010076365 Adiponectin Proteins 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 29
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 239000001569 carbon dioxide Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003151 transfection method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000010370 cell cloning Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 102000005396 glutamine synthetase Human genes 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000012257 pre-denaturation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 101100270918 Drosophila melanogaster Arp6 gene Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Abstract
The invention relates to the technical field of biology, in particular to a recombinant human adiponectin expression vector, a vector construction method and an expression method. The recombinant human adiponectin expression vector comprises a nucleotide sequence shown in SEQ ID No.1 and an Fc-GS plasmid. The construction method of the recombinant human adiponectin expression vector comprises the following steps: obtaining a cDNA sequence of the human adiponectin through codon optimization according to the amino acid sequence of the human adiponectin; the cDNA sequence of the human adiponectin is shown as SEQ ID No. 1; designing a primer, amplifying the cDNA sequence, and recovering a target fragment after identification; and connecting the target fragment to an Fc-GS plasmid to obtain a recombinant human adiponectin expression vector. The recombinant human adiponectin expression vector is transfected into hamster ovary cells, recombinant human adiponectin-Fc fusion protein can be stably expressed, and the method is simple and efficient.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a recombinant human adiponectin expression vector, a vector construction method and an expression method.
Background
Adiponectin (ADIP) is an adipocyte-specific expression adipocytokine secreted into plasma, with a monomer molecular weight of about 30kD, and is named Acrp 30. Under normal conditions, the expression level of adiponectin in the body is stable, the concentration is about 3-30 mug/mL, and the adiponectin accounts for 0.01 percent of the total protein content in plasma.
Adiponectin is believed to cause RNA to be expressed 100-fold more tissue-specifically during adipocyte differentiation than other tissues. The human adiponectin gene is located on chromosome 3q27, has a full length of 16Kbp, consists of three exons and two introns, comprises 244 amino acids, and is divided according to functions from an amino terminal to a carboxyl terminal: a signal peptide domain (1-18AA), an adiponectin specific domain (19-41AA), a collagen repeat domain (42-107AA) and a globular domain sequence (108-244 AA). The signal peptide itself is cleaved off during secretion, the adiponectin specific domain sequence has no significant homology to most protein sequences, while the adiponectin globular domain sequence has significant homology to many proteins. At the beginning of the collagen repeating structural domain, 7 complete 'Gly-X-Pro' repeating units are arranged in an aggregation way; in the terminal sequence of the collagen repeat domain, there are 22 incomplete "Gly-X-Y" repeat units scattered in a distribution, forming a "stalk" of the collagen structure. In human plasma, there are two major classes of adiponectin: monomeric forms of adiponectin and multimeric forms of adiponectin. The monomeric adiponectin is divided into two types, namely full-length adiponectin and adiponectin which is obtained by hydrolyzing full-length adiponectin by protease and only has a portion with a globular domain of adiponectin, and is called globular adiponectin. The dimeric adiponectin refers primarily to the trimeric form of adiponectin, with minor amounts of hexamer and higher molecular weight dimeric adiponectin also present.
Adiponectin can regulate glucose and lipid metabolism in liver, muscle, and fat; can directly act on heart, vascular cell and macrophage to exert cardioprotective and anti-inflammatory effects; can improve the survival rate of pancreatic beta cells and participate in resisting malignant tumors caused by obesity and insulin resistance; is closely related to immune status; recent studies have shown that adiponectin may also have some effects on osteoarthritis and bone metabolism, and thus, studies on adiponectin are of great significance.
However, there are several problems with the current studies on adiponectin: 1. adiponectin in its various forms and polymers may differ in its role; 2. the assessment of adiponectin by different investigators is not consistent. Therefore, it is important to develop a large amount of stably expressed recombinant human adiponectin proteins.
Disclosure of Invention
The technical problem to be solved by the invention is as follows: provided are a recombinant human adiponectin expression vector, a vector construction method and an expression method, wherein the constructed expression vector stably expresses recombinant human adiponectin-Fc fusion protein in hamster ovary cells, and the method is simple and efficient.
The invention provides a recombinant human adiponectin expression vector which comprises a nucleotide sequence shown in SEQ ID No.1 and Fc-GS plasmid.
The invention provides a construction method of a recombinant human adiponectin expression vector, which comprises the following steps:
step 1: obtaining a cDNA sequence of the human adiponectin through codon optimization according to the amino acid sequence of the human adiponectin; the cDNA sequence of the human adiponectin is shown as SEQ ID No. 1;
step 2: designing a primer, amplifying the cDNA sequence, and recovering a target fragment after identification;
and step 3: and connecting the target fragment to an Fc-GS plasmid to obtain a recombinant human adiponectin expression vector.
Preferably, the step 3 specifically comprises:
digesting the Fc-GS plasmid by using a first restriction enzyme, and then treating the Fc-GS plasmid for 20-40 minutes by using heat-sensitive phosphatase to inactivate the heat-sensitive phosphatase;
digesting the target fragment by using a second restriction enzyme; the first restriction enzyme and the second restriction enzyme are the same or are isocaudarner;
and connecting the Fc-GS plasmid subjected to restriction enzyme digestion and the target fragment overnight to obtain the recombinant human adiponectin expression vector.
Preferably, the first restriction enzyme is Bgl II and the second restriction enzyme is BamHI.
Preferably, after the step 3, the method further comprises:
digesting the recombinant human adiponectin expression vector by using Hind III and Xho I restriction endonucleases, and then carrying out agarose gel electrophoresis to identify the connection condition of target fragments;
and performing bidirectional sequencing on the recombinant human adiponectin expression vector to identify the inserted target fragment sequence.
The invention provides application of the recombinant human adiponectin expression vector in expressing human adiponectin-Fc fusion protein.
The invention provides an expression method of recombinant human adiponectin, which comprises the following steps:
step 1: transfecting the recombinant human adiponectin expression vector into hamster ovary cells by an electroporation transfection method;
step 2: screening hamster ovary cells transfected with the recombinant human adiponectin expression vector by using a MAX-containing culture medium;
and step 3: culturing the positive clone obtained after screening, extracting and separating protein to obtain the human adiponectin-Fc fusion protein.
Preferably, the hamster ovary cells have the endogenous glutamine synthetase gene knocked out of the cells by the CRISPR technique.
Preferably, the step 1 specifically comprises:
will be passedThe hamster ovary cells with endogenous glutamine synthetase gene knocked out by CRISPR technology are suspended in phosphate buffer to obtain cell suspension with the density of 1 × 107～1×108Cells/ml;
mixing the cell suspension with 20-30 μ g of the recombinant human adiponectin expression vector of claim 1, and performing electric shock.
Preferably, in step 3, after the protein is extracted and separated, the protein is identified and analyzed for concentration.
Compared with the prior art, the recombinant human adiponectin expression vector comprises the nucleotide sequence shown in SEQ ID No.1 and Fc-GS plasmid. The recombinant human adiponectin expression vector can transfect hamster ovary cells through electroporation, particularly positive clones can be screened out through a Glutamine Synthetase (GS) screening system in one turn, expression of human adiponectin-Fc fusion protein is rapidly and efficiently realized, and the recombinant human adiponectin expression vector is high in repeatability and good in universality. Experiments prove that the concentration of the fusion protein obtained by the method is at least 2mg/100ml, which is obviously higher than the concentration (0.2-1.35 mg/100ml) of the protein obtained by the existing eukaryotic cell cloning experiments.
The recombinant human adiponectin-Fc fusion protein is stably expressed in the CHO cell strain, a large amount of high-purity adiponectin protein can be prepared at one time, the method is simple and easy to implement, and the problems of complexity of biological amplification protein and corresponding high price are solved to a certain extent.
Drawings
FIG. 1 is an Fc-GS plasmid map;
FIG. 2 is a diagram showing the results of agarose gel electrophoresis after PCR amplification of cDNA;
FIG. 3 is a diagram showing the results of agarose gel electrophoresis after double digestion of ADIP-FC-GS plasmid;
FIG. 4 shows the sequencing results of the ADIP-FC-GS plasmid;
FIG. 5 is a graph showing SDS-PAGE electrophoresis results of proteins produced after transfection of hamster ovary cells with the ADIP-FC-GS plasmid;
FIG. 6 is a standard curve diagram of protein concentration for enzyme-linked immunoassay.
Detailed Description
For a further understanding of the invention, alternative embodiments of the invention are described below in conjunction with the examples, but it should be understood that these descriptions are included merely to further illustrate the features and advantages of the invention, and are not intended to limit the invention.
The embodiment of the invention discloses a recombinant human adiponectin expression vector, which comprises a nucleotide sequence shown in SEQ ID No.1 and Fc-GS plasmid.
The Fc-GS plasmid map is shown in FIG. 1.
The embodiment of the invention discloses a construction method of a recombinant human adiponectin expression vector, which comprises the following steps:
step 1: obtaining a cDNA sequence of the human adiponectin through codon optimization according to the amino acid sequence of the human adiponectin; the cDNA sequence of the human adiponectin is shown as SEQ ID No. 1;
the amino acid sequence of HUMAN adiponectin was obtained at NCBI and has the sequence number UniProtKB-Q15848(ADIPO _ HUMAN) as shown in SEQ ID No. 2. For sample purification and detection, His-tag and Flag-tag can be fused at the N terminal, and the amino acid sequence is shown as SEQ ID No.3, or the amino acid sequence after IgG-Fc fragment is fused at the C terminal, and the amino acid sequence is shown as SEQ ID No. 4.
Obtaining cDNA sequence after codon optimization.
Step 2: designing a primer, amplifying the cDNA sequence, and recovering a target fragment after identification;
the primers were designed as follows:
a forward primer: CTGGGATCCCAGGAGACCACAACCCAGG, respectively;
reverse primer: CGC GGATCCTCAATTGGTATCATGGTA, respectively;
the polymerase chain reaction total reaction system for amplifying the cDNA sequence is as follows: template cDNA 1. mu.L, forward primer 3. mu.L, reverse primer 3. mu.L, 5 XPrimeStar Buffer 6. mu.L, dNTPS (2.5mM each) 0.5. mu.L, Taq DNA Polymerase 0.5. mu.L, plus ddH2O to 30. mu.L. The reaction conditions are as follows: pre-denaturation at 95 ℃ for 5 min; denaturation at 95 ℃ for 30s, annealing at 58 ℃ for 30s, extension at 72 ℃ for 30s, and 25 cycles; extension at 72 ℃ for 5 min. The materials were purchased from Takara Bio, Beijing, China, Inc. (Beijing, Takara Bio)). After 10g/L agarose gel electrophoresis analysis, the PCR product is cut from about 748bp band.
The 748bp fragment is the target fragment.
And step 3: and connecting the target fragment to an Fc-GS plasmid to obtain a recombinant human adiponectin expression vector.
Optionally, step 3 specifically includes:
digesting the Fc-GS plasmid by using a first restriction enzyme, and then treating the Fc-GS plasmid for 20-40 minutes by using heat-sensitive phosphatase to inactivate the heat-sensitive phosphatase; the inactivation temperature is preferably 80-90 ℃, and the inactivation time is preferably 20-30 min;
digesting the target fragment by using a second restriction enzyme; the first restriction enzyme and the second restriction enzyme are the same or are isocaudarner;
and connecting the Fc-GS plasmid subjected to restriction enzyme digestion and the target fragment overnight to obtain the recombinant human adiponectin expression vector.
Optionally, the first restriction enzyme is Bgl II and the second restriction enzyme is BamHI.
The linker system of the Fc-GS plasmid and the target fragment after restriction enzyme digestion is:
6ul of the BamHI enzyme digested fragment of interest, 2ul of the treated Fc-GS plasmid, 1ul of Buffer, 1ul of T4 DNA ligase in total volume of 10ul, and ligated overnight at 16 ℃. Conventionally using CaCl2Method TOP10 competent bacteria were prepared, then the bacteria were transformed with the ligation mixture and the broth was plated on LB plates containing 100ug/ml AMP and incubated overnight. Miniprep plasmid using the centrifugal column extraction kit as usual. The above materials were purchased from major biotechnology companies, Shanghai, China.
Optionally, after the step 3, the method further includes:
digesting the recombinant human adiponectin expression vector by using Hind III and Xho I restriction endonucleases, and then carrying out agarose gel electrophoresis to identify the connection condition of target fragments;
and performing bidirectional sequencing on the recombinant human adiponectin expression vector to identify the inserted target fragment sequence.
The embodiment of the invention discloses application of the recombinant human adiponectin expression vector in the technical scheme in expression of human adiponectin-Fc fusion protein.
The embodiment of the invention also discloses an expression method of the recombinant human adiponectin, which comprises the following steps:
step 1: transfecting the recombinant human adiponectin expression vector into hamster ovary cells by an electroporation transfection method;
optionally, the hamster ovary cells have the endogenous glutamine synthetase gene knocked out of the cells by CRISPR technology.
Optionally, step 1 specifically includes:
suspending hamster ovary cells (CHO-K1) with endogenous glutamine synthetase gene knocked out by CRISPR technology in phosphate buffer to obtain cell suspension with density of 1 × 107～1×108Cells/ml;
and mixing the cell suspension with 20-30 mu g of the recombinant human adiponectin expression vector in the technical scheme, and performing electric shock.
Knocking out the endogenous glutamine synthetase gene of the cell, avoiding the endogenous influence of the host cell, reducing the false positive rate of cloning, reducing the dosage of MSX and shortening the time of cloning. Namely: the hamster ovary cells with the knocked-out endogenous glutamine synthetase gene are used as host cells for heterologous protein expression, and have the advantages of small screening pressure, short screening period, high cloning positive rate and the like. Tests show that more than 95% of cells in the cell culture screened by the system are positive clones.
In the electroporation transfection method, the voltage is preferably 270-280 v, the time is 15-20 ms, and the total discharge time is 18-25 ms.
Step 2: screening hamster ovary cells transfected with the recombinant human adiponectin expression vector by using a MAX-containing culture medium;
transfer hamster ovary cells transfected with recombinant human adiponectin expression vector to a culture dish, and add DMEM complete medium. Then, the cells were placed in a carbon dioxide incubator overnight for culture. After 2 to 3 days, the medium was replaced with a screening medium containing 50uM MSX (M5379, SIGMA, USA), and the culture was continued for about 10 to 15 days. After significant clones had formed, all cells in the dish were digested with pancreatin (C0201, bi yun day biotechnology), mixed and then used for scale-up culture to produce protein.
And step 3: culturing the positive clone obtained after screening, extracting and separating protein to obtain the human adiponectin-Fc fusion protein.
Specifically, positive clones obtained after screening were inoculated in a CD011 serum-free medium. The culture medium contained 1mg/L of insulin, and the concentration of carbon dioxide was 5%. Then placing the mixture on a carbon dioxide shaking bed, and carrying out shaking culture at 110-120 rpm for 10-15 days. The supernatant was collected by centrifugation. And extracting and separating protein from the supernatant by using a protein A chromatographic column.
Optionally, after the protein is extracted and separated, the protein is identified and analyzed for concentration.
Alternatively, the molecular weight of the isolated protein is identified using SDS-PAGE electrophoresis.
The molecular weight of the human adiponectin-Fc fusion protein is about 60 KD. The human adiponectin contains 226 amino acids after cutting off the secretory signal peptide and has the molecular weight of about 30 KD; the Fc protein consists of 229 amino acids and has a molecular weight of about 30KD, and the overall molecular weight of the two proteins is about 60KD after fusion.
Alternatively, the concentration of the isolated human adiponectin-Fc fusion protein is detected by enzyme-linked immunosorbent assay (ELISA).
The invention is further illustrated by the following examples:
EXAMPLE 1 construction of recombinant human adiponectin expression vector
Synthesizing a cDNA sequence shown as SEQ ID No. 1;
and carrying out PCR amplification on the cDNA sequence by taking the cDNA sequence as a template. The polymerase chain reaction total reaction system is as follows: template cDNA 1. mu.L, forward primer 3. mu.L, reverse primer 3. mu.L, 5 XPrimeStar Buffer 6. mu.L, dNTPS (2.5mM each) 0.5. mu.L, Taq DNA Polymerase 0.5. mu.L, plus ddH2O to 30. mu.L. The reaction conditions are as follows: pre-denaturation at 95 ℃ for 5 min; 95 deg.CDenaturation for 30s, annealing at 58 ℃ for 30s, and extension at 72 ℃ for 30s, for 25 cycles; extension at 72 ℃ for 5 min.
After 10g/L agarose gel electrophoresis analysis, the PCR product is cut from about 748bp band. Referring to FIG. 2, the electrophoresis result shows that a band is evident at 748bp, which is the target fragment. After the target fragment is recovered by agarose electrophoresis and recovered, the restriction enzyme digestion is carried out according to the following reaction system: 10ul of PCR fragment; k Buffer 2 ul; 1ul of BamHI enzyme; 7ul of water; the reaction was carried out at 37 ℃ for 2h in a total volume of 20 ul.
10ul of BglII digested Fc-GS plasmid was taken, treated with heat-sensitive phosphatase for 30min and then the phosphatase was inactivated at 80 ℃ for 20 min. 6ul of digested target fragment, 2ul of phosphatase-treated plasmid fragment, 1ul of Buffer, 1ul of T4 DNA ligase, total volume of 10ul, and ligation overnight at 16 ℃. Conventionally using CaCl2Method TOP10 competent bacteria were prepared, then the bacteria were transformed with the ligation mixture and the broth was plated on LB plates containing 100ug/ml AMP and incubated overnight. The ADIP-FC-GS plasmid was formed.
Taking 5ul of ADIP-FC-GS plasmid, 2ul of enzyme digestion reaction buffer solution, 1ul of Hind III restriction enzyme, 1ul of Xho I restriction enzyme and 11ul of deionized water, and placing the mixture in a water bath kettle at 37 ℃ for digestion for 2 hours after uniform mixing, wherein the total volume is 20 ul.
The expected size of the gene fragment for human adiponectin-FC is approximately 1434 bp. After double digestion, agarose gel electrophoresis was performed, and the results are shown in FIG. 3. In FIG. 3, there are actually 3 samples, in which the sizes of the cleaved fragments of the 1# and 2# samples are consistent with the expected values, and the 3# sample is a negative control.
The results of the two-way sequencing showed that the inserted gene sequence was identical to the human adiponectin gene sequence, and the sequencing map is shown in FIG. 4.
Example 2 expression of recombinant human adiponectin fusion protein in hamster ovary cells
The CRISPR technique knocked out the endogenous glutamine synthetase gene of CHO-K1 cells, and CHO-K1 cells (Invitrogen) in logarithmic growth phase were taken, trypsinized, and then resuspended in PBS solution to adjust the density to about 1X 107Cells/ml. The cell suspension was mixed with 20ug ADIP-FC-GS plasmid,standing on ice for 5 min. The cell suspension was transferred to a pre-cooled electroporation cuvette (165- & 2081, Biorad, 0.4ml capacity, 0.4cm gap) and the electroporator was adjusted to square wave mode with voltage 280v, time 20ms, one electroporation, total discharge time 20 ms. The cells were transferred to a 10cm dish and 10ml of DMEM complete medium was added. Then, the cells were placed in a carbon dioxide incubator overnight for culture. On day 2, the medium was changed to a selection medium containing 50uM MSX (M5379, SIGMA, USA), and the culture was continued for about 14 days. After significant clones had formed, all cells in the dish were digested with pancreatin (C0201, bi yun day biotechnology) and mixed. A portion was frozen in liquid nitrogen. The other part is used for producing the human adiponectin-FC protein by amplification culture.
Cells were seeded in 300ml of CD011 serum-free medium. The culture medium contained 1mg/L of insulin, and the concentration of carbon dioxide was 5%. Then, the cells were placed on a carbon dioxide shaker and cultured with shaking at 110rpm for 10 days. The supernatant was collected by centrifugation at 10000 rpm. A Protein A column (11-0034-94, general electric GE Healthcare, 10X 50mm) was equilibrated with 15ml PBS. The supernatant was applied to a centrifugal column for chromatography. After the sample was run, the column was washed with 15ml PBS. The protein was eluted with 5ml of glycine buffer pH 3.5 and collected stepwise at 1 ml/tube. The fractions eluted containing the protein were pooled and the buffer was changed to PBS using an ultrafiltration tube. The protein concentration was diluted to 100ug/ml with PBS solution. Filtering with 0.2um filter, and aseptically packaging.
40ul of the purified protein solution was mixed with 10ul of Load Buffer and boiled at 100 ℃ for 2 minutes. SDS-PAGE was then routinely performed. Referring to FIG. 5, M is Marker, 1 is the experimental sample, and 2 is the recombinant human adiponectin protein purchased from the outside. Electrophoresis results show that the molecular weight of the synthesized human adiponectin-Fc fusion protein is about 60KD, and is the same as the molecular weight of the recombinant human adiponectin globular protein purchased in the market.
The ELISA kit (enzyme-linked Biotechnology Co., Ltd., Shanghai, China) was used for the measurement according to the kit instructions. A log-log standard curve was plotted for the series of adiponectin concentrations.
TABLE 1 determination of OD values of samples
The system can obtain about 200ml of fermentation liquor. The OD values of each standard and diluted sample determined by ELISA are shown in table 1. The standard curve of protein concentration for ELISA assay and the fitting equation are shown in FIG. 6. Total protein concentration-concentration x dilution fold calculated from the standard curve. The total protein concentration was calculated to be 20ug/ml and the amount of protein was calculated to be 2mg/100 ml.
In the prior art, the concentration of protein obtained by eukaryotic cell cloning experiments is 0.2-1.35 mg/100ml more. Therefore, the preparation method for stably expressing the recombinant human adiponectin-Fc fusion protein in the CHO cell strain can prepare a large amount of adiponectin protein with high purity at one time, is simple and easy to implement, solves the problems of complexity and corresponding high price of biological amplification protein to a certain extent, and is a test preparation means with good prospect.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (10)
1. A recombinant human adiponectin expression vector is characterized by comprising a nucleotide sequence shown as SEQ ID No.1 and an Fc-GS plasmid.
2. A construction method of a recombinant human adiponectin expression vector is characterized by comprising the following steps:
step 1: obtaining a cDNA sequence of the human adiponectin through codon optimization according to the amino acid sequence of the human adiponectin; the cDNA sequence of the human adiponectin is shown as SEQ ID No. 1;
step 2: designing a primer, amplifying the cDNA sequence, and recovering a target fragment after identification;
and step 3: and connecting the target fragment to an Fc-GS plasmid to obtain a recombinant human adiponectin expression vector.
3. The construction method according to claim 2, wherein the step 3 is specifically:
digesting the Fc-GS plasmid by using a first restriction enzyme, and then treating the Fc-GS plasmid for 20-40 minutes by using heat-sensitive phosphatase to inactivate the heat-sensitive phosphatase;
digesting the target fragment by using a second restriction enzyme; the first restriction enzyme and the second restriction enzyme are the same or are isocaudarner;
and connecting the Fc-GS plasmid subjected to restriction enzyme digestion and the target fragment overnight to obtain the recombinant human adiponectin expression vector.
4. The method according to claim 3, wherein the first restriction enzyme is Bgl II and the second restriction enzyme is BamHI.
5. The building method according to claim 2, wherein after the step 3, the method further comprises:
digesting the recombinant human adiponectin expression vector by using Hind III and Xho I restriction endonucleases, and then carrying out agarose gel electrophoresis to identify the connection condition of target fragments;
and performing bidirectional sequencing on the recombinant human adiponectin expression vector to identify the inserted target fragment sequence.
6. Use of the recombinant human adiponectin expression vector of claim 1 for expressing a human adiponectin-Fc fusion protein.
7. A method for expressing recombinant human adiponectin, which comprises the following steps:
step 1: transfecting the recombinant human adiponectin expression vector of claim 1 into hamster ovary cells by electroporation transfection;
step 2: screening hamster ovary cells transfected with the recombinant human adiponectin expression vector by using a MAX-containing culture medium;
and step 3: culturing the positive clone obtained after screening, extracting and separating protein to obtain the human adiponectin-Fc fusion protein.
8. The expression method according to claim 7, wherein the hamster ovary cells have been knocked out of the cell's endogenous glutamine synthetase gene by CRISPR technique.
9. The expression method according to claim 8, wherein the step 1 specifically comprises:
suspending hamster ovary cells with endogenous glutamine synthetase gene knocked out by CRISPR technology in phosphate buffer to obtain cell suspension with density of 1 × 107～1×108Cells/ml;
mixing the cell suspension with 20-30 μ g of the recombinant human adiponectin expression vector of claim 1, and performing electric shock.
10. The expression method according to claim 7, wherein in step 3, after the protein is extracted and separated, the protein is identified and analyzed for concentration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910966965.9A CN112646837A (en) | 2019-10-12 | 2019-10-12 | Recombinant human adiponectin expression vector, vector construction method and expression method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910966965.9A CN112646837A (en) | 2019-10-12 | 2019-10-12 | Recombinant human adiponectin expression vector, vector construction method and expression method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112646837A true CN112646837A (en) | 2021-04-13 |
Family
ID=75343666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910966965.9A Pending CN112646837A (en) | 2019-10-12 | 2019-10-12 | Recombinant human adiponectin expression vector, vector construction method and expression method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112646837A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114957410A (en) * | 2022-06-08 | 2022-08-30 | 华兰基因工程有限公司 | Preparation method of surface protein receptor binding region of kappa strain 2019-nCoV |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1477113A (en) * | 2002-08-21 | 2004-02-25 | 湖南盈程生命科学研究所有限公司 | Recombinant human fatty acid oxidation protein, its production method and application |
| US20090197806A1 (en) * | 2006-01-09 | 2009-08-06 | Morrow Ardythe L | Adiponectin for treatment of various disorders |
| CN102690353A (en) * | 2011-03-25 | 2012-09-26 | 温州医学院 | Method for rapid screening of modified tumor necrosis factor receptor II-adiponectin globular-site fusion protein and application thereof |
| CN104302659A (en) * | 2012-02-29 | 2015-01-21 | Ambrx公司 | Modified adiponectin polypeptides and their uses |
| CN105950622A (en) * | 2016-05-19 | 2016-09-21 | 苏州康聚生物科技有限公司 | GS (glutamine synthetase) gene specific identification crRNA and application thereof |
| CN108085337A (en) * | 2017-12-28 | 2018-05-29 | 未名生物医药有限公司 | A kind of screening technique of GS expression systems cell line |
-
2019
- 2019-10-12 CN CN201910966965.9A patent/CN112646837A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1477113A (en) * | 2002-08-21 | 2004-02-25 | 湖南盈程生命科学研究所有限公司 | Recombinant human fatty acid oxidation protein, its production method and application |
| US20090197806A1 (en) * | 2006-01-09 | 2009-08-06 | Morrow Ardythe L | Adiponectin for treatment of various disorders |
| CN102690353A (en) * | 2011-03-25 | 2012-09-26 | 温州医学院 | Method for rapid screening of modified tumor necrosis factor receptor II-adiponectin globular-site fusion protein and application thereof |
| CN104302659A (en) * | 2012-02-29 | 2015-01-21 | Ambrx公司 | Modified adiponectin polypeptides and their uses |
| CN105950622A (en) * | 2016-05-19 | 2016-09-21 | 苏州康聚生物科技有限公司 | GS (glutamine synthetase) gene specific identification crRNA and application thereof |
| CN108085337A (en) * | 2017-12-28 | 2018-05-29 | 未名生物医药有限公司 | A kind of screening technique of GS expression systems cell line |
Non-Patent Citations (4)
| Title |
|---|
| KIM,Y.等: "adiponectin precursor [Homo sapiens]", 《GENBANK》 * |
| YOUN，B.S.等: "Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus", 《THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM》 * |
| 佘其美等: "重组人脂联素真核表达载体的构建及表达", 《中国现代医学杂志》 * |
| 李丙蓉等: "人脂联素基因真核表达载体的构建及在HEK293细胞中的表达", 《中华内分泌代谢杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114957410A (en) * | 2022-06-08 | 2022-08-30 | 华兰基因工程有限公司 | Preparation method of surface protein receptor binding region of kappa strain 2019-nCoV |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021083072A1 (en) | Human collagen 17-type polypeptide, production method therefor and use thereof | |
| CN107384897B (en) | Alkaline protease, gene and application thereof | |
| JP2020528760A (en) | Use in the preparation of novel fusion proteins and the improvement of their protein synthesis | |
| KR101026526B1 (en) | Method for the secretory production of heterologous protein in Escherichia coli | |
| CN114317576A (en) | Human growth hormone recombinant expression vector, engineering bacterium for expressing human growth hormone, construction method and application thereof | |
| CN110628738B (en) | Method for improving activity of glucose oxidase, mutant and application thereof | |
| CN106939315B (en) | Preparation method and application of oxalate decarboxylase | |
| CN112646837A (en) | Recombinant human adiponectin expression vector, vector construction method and expression method | |
| CN114761553A (en) | Nucleic acids, vectors, host cells and methods for producing beta-fructofuranosidase from aspergillus niger | |
| CN102206282A (en) | Efficient method for producing Trx-hCTRP2 | |
| CN116555320A (en) | Recombinant human-derived III-type triple helix collagen engineering bacterium, and construction method and application thereof | |
| CN113249288B9 (en) | Recombinant bacterium for expressing GLP-1 analogue and application thereof | |
| CN110819609B (en) | Mutant lipase with improved thermal stability as well as preparation method and application thereof | |
| CN112646044B (en) | TFF2-Fc fusion protein and high-efficiency expression production method thereof | |
| CN109320597B (en) | Fox subfamily activin A protein and preparation and application thereof | |
| CN109022471B (en) | Escherichia coli expression system for producing oxalate oxidase, and production method and application of oxalate oxidase | |
| CN111849795A (en) | Preparation method of heterodimer snake venom protein | |
| CN102277327B (en) | Colon bacillus for over-expressing RimL and application on preparing N-extrasin alpha acetylate | |
| CN108085332B (en) | Recombinant yeast with cell surface displaying bean hull peroxidase and construction method and application thereof | |
| CN111850022A (en) | Method for quickly adding or replacing protein tag of target gene | |
| CN111876436A (en) | Methionine lyase and coding gene and application thereof | |
| JPWO2020045472A5 (en) | ||
| CN113480666B (en) | CA153 fusion protein and preparation method thereof, and CA153 detection quality control product or calibrator | |
| CN104293737B (en) | A kind of host cell comprising expressive function recombinant human blood coagulation factors VII carrier and its high level expression method | |
| CN114409800B (en) | Method for preparing recombinant cystatin C |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210413 |